An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Fasenra

Chemical Namebenralizumab
Dosage FormInjectable (subcutaneous; 30 mg/mL)
Drug ClassMonoclonal antibodies
SystemRespiratory
CompanyAstraZeneca
Approval Year2017

Indication

  • Fasenra is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
Last updated on 2/3/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Fasenra (benralizumab) Prescribing Information 2019AstraZeneca
Document TitleYearSource
CADTH Canadian Drug Expert Committee Recommendation – Benralizumab (Fasenra). 2019CADTH
Benralizumab for treating severe eosinophilic asthma. 2019NICE
Document TitleYearSource
Comparative efficacy and safety of dupilumab and benralizumab in patients with inadequately controlled asthma: A systematic review. 2020International Journal of Molecular Sciences
Effect of monoclonal antibody drug therapy on mucosal biomarkers in airway disease: a systematic review. 2020Clinical and Experimental Allergy
Anti‐IL‐5 therapies for chronic obstructive pulmonary disease2020Cochrane Database of Systematic Reviews
Adverse events of benralizumab in moderate to severe eosinophilic asthma: A meta-analysis. 2019Medicine (Baltimore)
Monoclonal antibodies in type 2 asthma: A systematic review and network meta-analysis. 2019BMC Respiratory Journal
Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review. 2018European Respiratory Journal
Anti‐IL5 therapies for asthma. 2017Cochrane Database of Systematic Reviews
Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials. 2017Journal of Asthma
Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: A systematic review and meta-analysis. 2016PLoS One
Document TitleYearSource
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma. 2020Allergy
Global strategy for asthma management and prevention. 2020GINA
Recognition and management of severe asthma: a Canadian thoracic society position statement. 2017Canadian Journal of Respiratory, Critical Care, and Sleep Medicine